Skip to content

Transient Elastography in Hepatectomy for Hepatocellular Carcinoma

Value of Transient Elastography in Predicting Postoperative Liver Failure in Patients Undergoing Liver Resection for Hepatocellular Carcinoma.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01441453
Enrollment
120
Registered
2011-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2011-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma, Surgery

Keywords

Hepatocellular carcinoma, Cirrhosis, Liver resection, FibroScan

Brief summary

The purpose of this study is to determine whether liver transient elastography performed before the surgical procedure is able to predict liver failure in patients undergoing hepatectomy for hepatocellular carcinoma.

Interventions

PROCEDUREFibroScan (Transient Elastography measurement)

Preoperative evaluation of liver stiffness through FibroScan

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients already scheduled to undergo liver resection fo hepatocellular carcinoma

Design outcomes

Primary

MeasureTime frameDescription
Cut-off value of liver stiffness measured in kilopascal (kPa) able to predict the occurrence of postoperative liver failure.Participants will be followed for the duration of postoperative hospital stay, an expected average of 4 weeksDefinition of the cut-off value in kPa able to predict postoperative liver failure, i.e. the presence of at least one of the following variables: ascites causing a delay in the removal of surgical drainages and/or requiring paracentesis; increase of bilirubin levels \>3 mg/dL; alteration of coagulation factors requiring plasma infusion with an INR above 1.50 (with serum bilirubin levels \<12mg/dL); renal impairment, defined as blood urea nitrogen \>2.00 g/L and/or increase of serum creatinine \>2.00 mg/dL requiring only loop diuretics, dopamine/terlipressin, or dialysis.

Countries

Italy

Contacts

Primary ContactMatteo Cescon, MD, PhD
matteo.cescon@unibo.it+39-51-6364810

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026